IITRI is now in custody of the SARS-CoV-2 strain responsible for Covid-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this coronavirus.

IITRI provides IND-enabling vaccine programs, with over 30 years of experience conducting GLP-compliant toxicology studies. We support vaccine basic research through FDA approval programs for sponsors from government, biotech, academic, and pharma institutions.

Our team would love to speak to anyone looking to test their candidates, contact us here.